Aldeyra Therapeutics (ALDX) Non Operating Income (2013 - 2026)
Aldeyra Therapeutics' (ALDX) quarterly Non Operating Income came in at $94299.0 in Q1 2026, down 81.06% YoY from $497958.0 in Q1 2025, and down 54.31% on a QoQ basis from $206376.0 in Q4 2025.
Aldeyra Therapeutics (ALDX) Non Operating Income (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics (ALDX) has 14 years of Non Operating Income data on file, last reported at $94299.0 in Q1 2026.
- Quarterly Non Operating Income fell 81.06% year-over-year to $94299.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 million (down 70.6% YoY) and the FY2025 annual result came in at $1.4 million, down 66.74% from the prior year.
- Non Operating Income eased to $94299.0 in Q1 2026, from $206376.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $1.4 million in Q3 2023 to a low of -$304585.0 in Q1 2022.
- A 5-year average of $687373.9 and a median of $769017.0 in 2024 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2023 — Non Operating Income jumped 2153.5% — and 2026, when it sank 81.06%.
- Tracing ALDX's Non Operating Income over 5 years: stood at $794629.0 in 2022, then soared by 69.24% to $1.3 million in 2023, then plunged by 42.82% to $769017.0 in 2024, then sank by 73.16% to $206376.0 in 2025, then plunged by 54.31% to $94299.0 in 2026.
- The last three Non Operating Income figures came in at $94299.0 (Q1 2026), $206376.0 (Q4 2025), and $312791.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Aldeyra Therapeutics | 90.18 Mn | 90.18 Mn | - | 400,234.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 400,234.00 |
| Mar 31, 2026 | 94,299.00 |
| Dec 31, 2025 | 206,376.00 |
| Sep 30, 2025 | 312,791.00 |
| Jun 30, 2025 | 401,420.00 |
| Mar 31, 2025 | 497,958.00 |
| Dec 31, 2024 | 769,017.00 |
| Sep 30, 2024 | 1.02 Mn |
| Jun 30, 2024 | 1.16 Mn |
| Mar 31, 2024 | 1.31 Mn |
| Dec 31, 2023 | 1.34 Mn |
| Sep 30, 2023 | 1.36 Mn |
| Jun 30, 2023 | 1.36 Mn |
| Mar 31, 2023 | 1.19 Mn |
| Dec 31, 2022 | 794,629.00 |
| Sep 30, 2022 | 231,325.00 |
| Jun 30, 2022 | -66,017.00 |
| Mar 31, 2022 | -304,585.00 |
| Dec 31, 2021 | -350,304.00 |
| Sep 30, 2021 | -353,804.00 |